Chiltern says strategic deals are good for the CRO sector

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology Big pharma

Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market.

Outsourcing-pharma.com spoke with Aize Smink, Chiltern’s senior executive VP, global clinical development, who said that the drug industry’s need for efficiency is driving the formation of such deals.

He explained that these types of collaboration are not limited to Big Pharma, citing the UK-headquartered CROs agreement with a number of mid-sized drug makers as evidence.

“[Strategic partnering] allows us to focus on the long term and look at process improvement in a collaborative way with our pharma partners. So it also drives progress for CROs in that sense​.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars